NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade

Next Previous
Trial Profile

NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; NTBI 1301; NY ESO-1 loaded dendritic cell vaccine
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 1 Feb 2019 to 17 Jul 2020.
    • 12 Sep 2017 Planned primary completion date changed from 1 Feb 2019 to 17 Jul 2019.
    • 08 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top